N
NeuroSync
Neuro-technology with foundational ip in eye-tracking metrics and devices
About NeuroSync
NeuroSync Inc., operating as neurosync.health, is a neurotechnology firm providing a digital health platform for brain health applications. Originally founded as SyncThink in 2009 by Dr. Jam Ghajar, a neurosurgeon, the company rebranded in 2022 to better reflect its expanding focus on the broader neurological healthcare market. Dr. Ghajar's background as the founder of the Brain Trauma Foundation underpins the company's clinical and research-driven approach. The company is headquartered in Holliston, Massachusetts, and has a presence in Palo Alto, California. A significant milestone was achieved in September 2022 when the company, then known as SyncThink, rebranded to NeuroSync under a new executive team to accelerate its growth within the larger neuro-healthcare landscape.
The company's core business revolves around a digital platform that utilizes artificial intelligence and objective measurements to assess brain health, provide therapy, and enhance cognitive performance. NeuroSync serves a diverse client base that includes healthcare organizations, biopharmaceutical companies, sports teams, and the military. Clients use the platform for various purposes, from identifying neurological deficits and monitoring treatment responses to planning targeted training programs. The business model involves providing access to its proprietary software and analytics, with revenue generated from partnerships and the sale of its integrated technology solutions. Key partners include Stanford University, Magic Leap, and the Department of Defense.
NeuroSync's flagship product is EYE-SYNC®, an FDA-cleared technology that uses eye-tracking within a virtual reality (VR) headset to assess brain health. The platform comes as a package including a VR headset, a tablet, and a suite of eye-tracking assessments. EYE-SYNC can analyze eye movements as an aid in diagnosing conditions like concussions and is backed by numerous patents and peer-reviewed publications. It provides clinicians with detailed reports, metrics, and visuals to describe a patient's performance, identifying the type and severity of dysfunction. A second product, PRO-SYNC, is a non-medical wellness application designed to track and enhance sleep quality and mental acuity by monitoring eye movements, providing users with a readiness score. Unlike EYE-SYNC, which is a registered medical device, PRO-SYNC is positioned as a general wellness tool. Both products leverage proprietary algorithms to quantify synchronization abilities and provide actionable data in minutes.
Source: Dealroom company dataAt a glance
- Founded
- 2008
- Headquarters
- Holliston, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Alan Quasha
Quadrant Management
US Department of War- BFBrain Trauma Foundation
MassChallenge
StartUp Health
Delaware Division of Small Business
Series A1 investor entered at this stage
Oceanic Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuroSync on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroSync on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.